{"id":9665,"date":"2026-03-18T11:12:29","date_gmt":"2026-03-18T03:12:29","guid":{"rendered":"https:\/\/regask.com\/?p=9665"},"modified":"2026-03-18T11:12:29","modified_gmt":"2026-03-18T03:12:29","slug":"ema-ouvre-les-candidatures-pour-les-reunions-de-portefeuille-et-de-technologie-de-2026-destinees-aux-grandes-entreprises-pharmaceutiques","status":"publish","type":"post","link":"https:\/\/regask.com\/fr\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/","title":{"rendered":"L\u2019EMA ouvre les candidatures pour son portefeuille et ses technologies 2026\u2026"},"content":{"rendered":"<p><span data-contrast=\"auto\">Sur\u00a0<\/span><b><span data-contrast=\"auto\">10 mars 2026<\/span><\/b><span data-contrast=\"auto\">, le\u00a0<\/span><b><span data-contrast=\"auto\">Agence europ\u00e9enne des m\u00e9dicaments (EMA)<\/span><\/b><span data-contrast=\"auto\">\u00a0a annonc\u00e9 que les candidatures sont d\u00e9sormais ouvertes pour\u00a0<\/span><b><span data-contrast=\"auto\">R\u00e9unions sur le portefeuille et la technologie (PTM)<\/span><\/b><span data-contrast=\"auto\">\u00a0pr\u00e9vu pour le\u00a0<\/span><b><span data-contrast=\"auto\">seconde moiti\u00e9 de 2026<\/span><\/b><span data-contrast=\"auto\">. Le programme invite\u00a0<\/span><b><span data-contrast=\"auto\">grandes entreprises pharmaceutiques poss\u00e9dant de vastes portefeuilles de produits m\u00e9dicinaux<\/span><\/b><span data-contrast=\"auto\">\u00a0entamer des discussions structur\u00e9es avec l&#039;agence.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Ces\u00a0<\/span><b><span data-contrast=\"auto\">r\u00e9unions virtuelles et gratuites<\/span><\/b><span data-contrast=\"auto\">\u00a0sont con\u00e7us pour r\u00e9pondre\u00a0<\/span><b><span data-contrast=\"auto\">d\u00e9fis li\u00e9s au d\u00e9veloppement du portefeuille de produits<\/span><\/b><span data-contrast=\"auto\">, capturer\u00a0<\/span><b><span data-contrast=\"auto\">technologies \u00e9mergentes et disruptives<\/span><\/b><span data-contrast=\"auto\">, et aider l&#039;EMA \u00e0 anticiper\u00a0<\/span><b><span data-contrast=\"auto\">L&#039;expertise scientifique et r\u00e9glementaire est n\u00e9cessaire pour les futures demandes d&#039;autorisation de mise sur le march\u00e9.<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Les entreprises int\u00e9ress\u00e9es \u00e0 participer doivent soumettre le formulaire d\u00e9sign\u00e9\u00a0<\/span><b><span data-contrast=\"auto\">Formulaire de demande PTM \u00e0 soumettre avant le 30 avril 2026<\/span><\/b><span data-contrast=\"auto\">.L&#039;EMA examinera les dossiers et informera les candidats de sa d\u00e9cision.\u00a0<\/span><b><span data-contrast=\"auto\">d&#039;ici fin mai 2026<\/span><\/b><span data-contrast=\"auto\">.<\/span><\/p>\n<div class=\"row\"  id=\"row-412806181\">\n\n\t<div id=\"col-1757790500\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"gap-617149421\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-617149421 {\n  padding-top: 20px;\n}\n<\/style>\n\t<\/div>\n\t\n<h2>D\u00e9tails de la mise \u00e0 jour<\/h2>\n\t<div id=\"gap-2009237606\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-2009237606 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">Le\u00a0<\/span><b><span data-contrast=\"auto\">R\u00e9unions sur le portefeuille et la technologie (PTM)<\/span><\/b><span data-contrast=\"auto\">\u00a0offrir aux grandes entreprises pharmaceutiques l&#039;occasion de discuter\u00a0<\/span><b><span data-contrast=\"auto\">Consid\u00e9rations r\u00e9glementaires et scientifiques \u00e0 l&#039;\u00e9chelle du portefeuille<\/span><\/b><span data-contrast=\"auto\">\u00a0directement avec l&#039;EMA. Les r\u00e9unions sont men\u00e9es\u00a0<\/span><b><span data-contrast=\"auto\">virtuellement et sans frais pour les candidats<\/span><\/b><span data-contrast=\"auto\">, en abaissant les obstacles \u00e0 la participation tout en permettant un engagement strat\u00e9gique.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Le programme est sp\u00e9cifiquement con\u00e7u pour aider \u00e0 identifier\u00a0<\/span><b><span data-contrast=\"auto\">probl\u00e8mes affectant le d\u00e9veloppement du portefeuille de produits<\/span><\/b><span data-contrast=\"auto\">\u00a0et faciliter le dialogue sur\u00a0<\/span><b><span data-contrast=\"auto\">technologies innovantes et disruptives<\/span><\/b><span data-contrast=\"auto\">\u00a0qui pourraient influencer les futures \u00e9valuations r\u00e9glementaires. \u00c0 travers ces discussions, l&#039;EMA vise \u00e0 harmoniser ses\u00a0<\/span><b><span data-contrast=\"auto\">comp\u00e9tences scientifiques et r\u00e9glementaires<\/span><\/b><span data-contrast=\"auto\">\u00a0avec les besoins \u00e9volutifs des pipelines industriels.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Si une demande de r\u00e9union est accept\u00e9e, les demandeurs doivent soumettre un\u00a0<\/span><b><span data-contrast=\"auto\">document d&#039;information compl\u00e9t\u00e9<\/span><\/b><span data-contrast=\"auto\">\u00a0en utilisant le\u00a0<\/span><b><span data-contrast=\"auto\">Mod\u00e8le fourni par l&#039;EMA (Num\u00e9ro de r\u00e9f\u00e9rence : EMA\/571070\/2023)<\/span><\/b><span data-contrast=\"auto\">. Ce document doit \u00eatre remis\u00a0<\/span><b><span data-contrast=\"auto\">quatre \u00e0 six semaines avant la r\u00e9union pr\u00e9vue via Eudralink<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">De plus, les candidats doivent soumettre un\u00a0<\/span><b><span data-contrast=\"auto\">pr\u00e9sentation pr\u00e9alable \u00e0 la r\u00e9union et liste des participants une semaine avant la date de la r\u00e9union<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1757790500 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-770540314\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Date limite de retour d&#039;information<\/h2>\n\t<div id=\"gap-1619122064\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1619122064 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">Le\u00a0<\/span><b><span data-contrast=\"auto\">La date limite pour soumettre le formulaire de candidature \u00e0 la r\u00e9union sur le portefeuille et la technologie est le 30 avril 2026.<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Le\u00a0<\/span><b><span data-contrast=\"auto\">L\u2019Agence europ\u00e9enne des m\u00e9dicaments communiquera les r\u00e9sultats des demandes et les prochaines \u00e9tapes d\u2019ici fin mai 2026.<\/span><\/b><span data-contrast=\"auto\">, avec des r\u00e9unions approuv\u00e9es pr\u00e9vues pendant la\u00a0<\/span><b><span data-contrast=\"auto\">seconde moiti\u00e9 de 2026<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-770540314 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-454869622\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Pourquoi c&#039;est important<\/h2>\n\t<div id=\"gap-1226727984\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1226727984 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">Le\u00a0<\/span><b><span data-contrast=\"auto\">Programme PTM<\/span><\/b><span data-contrast=\"auto\">\u00a0offre une opportunit\u00e9 structur\u00e9e aux entreprises avec\u00a0<\/span><b><span data-contrast=\"auto\">grands pipelines de produits m\u00e9dicinaux<\/span><\/b><span data-contrast=\"auto\">\u00a0pour aborder\u00a0<\/span><b><span data-contrast=\"auto\">d\u00e9fis li\u00e9s au d\u00e9veloppement transversal et aux technologies \u00e9mergentes<\/span><\/b><span data-contrast=\"auto\">\u00a0avec les organismes de r\u00e9glementation d\u00e8s le d\u00e9but.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">En favorisant un dialogue pr\u00e9coce, l&#039;initiative soutient\u00a0<\/span><b><span data-contrast=\"auto\">strat\u00e9gie r\u00e9glementaire proactive<\/span><\/b><span data-contrast=\"auto\">, am\u00e9liore\u00a0<\/span><b><span data-contrast=\"auto\">alignement sur les attentes scientifiques<\/span><\/b><span data-contrast=\"auto\">, et contribue \u00e0 r\u00e9duire\u00a0<\/span><b><span data-contrast=\"auto\">incertitude r\u00e9glementaire future<\/span><\/b><span data-contrast=\"auto\">\u00a0\u00e0 travers des portefeuilles complexes, y compris\u00a0<\/span><b><span data-contrast=\"auto\">nouvelles modalit\u00e9s, produits biologiques et th\u00e9rapies avanc\u00e9es<\/span><\/b><span data-contrast=\"auto\">. Le\u00a0<\/span><b><span data-contrast=\"auto\">format virtuel et sans frais<\/span><\/b><span data-contrast=\"auto\">\u00a0am\u00e9liore encore l&#039;accessibilit\u00e9 pour les organisations admissibles.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-454869622 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-705670426\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>\u00c0 qui cela s&#039;adresse-t-il ?<\/h2>\n\t<div id=\"gap-1581112975\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1581112975 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Cette annonce est particuli\u00e8rement pertinente pour <strong>\u00c9quipes des affaires r\u00e9glementaires, des affaires m\u00e9dicales, de la recherche et du d\u00e9veloppement et du commerce<\/strong> au sein des entreprises pharmaceutiques, gestion <strong>portefeuilles de produits m\u00e9dicinaux importants<\/strong>. Ces fonctions jouent un r\u00f4le cl\u00e9 dans la pr\u00e9paration des demandes de PTM, l&#039;identification des probl\u00e8mes transversaux et la coordination des documents d&#039;information qui abordent les consid\u00e9rations scientifiques, r\u00e9glementaires et strat\u00e9giques li\u00e9es au pipeline.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-705670426 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-212464744\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Prochaines \u00e9tapes<\/h2>\n\t<div id=\"gap-1582056273\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1582056273 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">Les organisations qui pr\u00e9voient de participer devraient entamer rapidement une coordination interne afin d&#039;assurer la pr\u00e9paration et la soumission en temps voulu des\u00a0<\/span><b><span data-contrast=\"auto\">Formulaire de candidature pour la r\u00e9union sur le portefeuille et la technologie (PTM) \u00e0 soumettre avant le 30 avril 2026<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559683&quot;:0,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:&#091;8226&#093;,&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"1\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">\u00c9quipes des affaires r\u00e9glementaires<\/span><\/b><span data-contrast=\"auto\">\u00a0devrait d&#039;abord \u00e9valuer\u00a0<\/span><b><span data-contrast=\"auto\">admissibilit\u00e9 du portefeuille<\/span><\/b><span data-contrast=\"auto\">, remplissez et soumettez le\u00a0<\/span><b><span data-contrast=\"auto\">application PTM<\/span><\/b><span data-contrast=\"auto\">, et si la demande de r\u00e9union est approuv\u00e9e, coordonner la pr\u00e9paration de\u00a0<\/span><b><span data-contrast=\"auto\">Document d&#039;information de l&#039;EMA (EMA\/571070\/2023)<\/span><\/b><span data-contrast=\"auto\">\u00a0et g\u00e9rer le\u00a0<\/span><b><span data-contrast=\"auto\">Soumission \u00e0 Eudralink quatre \u00e0 six semaines avant la r\u00e9union pr\u00e9vue<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559683&quot;:0,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:&#091;8226&#093;,&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"2\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">\u00e9quipes des affaires m\u00e9dicales<\/span><\/b><span data-contrast=\"auto\">\u00a0devrait identifier\u00a0<\/span><b><span data-contrast=\"auto\">questions scientifiques et de d\u00e9veloppement transversales<\/span><\/b><span data-contrast=\"auto\">\u00a0qui pourrait n\u00e9cessiter des discussions r\u00e9glementaires et une collaboration \u00e9troite avec les affaires r\u00e9glementaires pour fa\u00e7onner le\u00a0<\/span><b><span data-contrast=\"auto\">Ordre du jour de la r\u00e9union et \u00e9l\u00e9ments d&#039;information<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559683&quot;:0,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:&#091;8226&#093;,&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"3\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">\u00c9quipes de recherche et d\u00e9veloppement<\/span><\/b><span data-contrast=\"auto\">\u00a0devrait contribuer\u00a0<\/span><b><span data-contrast=\"auto\">pour traiter des donn\u00e9es et des sujets li\u00e9s \u00e0 la technologie li\u00e9s aux pipelines<\/span><\/b><span data-contrast=\"auto\">, y compris\u00a0<\/span><b><span data-contrast=\"auto\">modalit\u00e9s nouvelles ou disruptives<\/span><\/b><span data-contrast=\"auto\">, pour inclusion dans le\u00a0<\/span><b><span data-contrast=\"auto\">document d&#039;information et pr\u00e9sentation pr\u00e9alable \u00e0 la r\u00e9union<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559683&quot;:0,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:&#091;8226&#093;,&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"4\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">\u00c9quipes commerciales et marketing<\/span><\/b><span data-contrast=\"auto\">\u00a0devrait fournir des commentaires sur\u00a0<\/span><b><span data-contrast=\"auto\">priorit\u00e9s en mati\u00e8re de strat\u00e9gie de portefeuille et de gestion du cycle de vie<\/span><\/b><span data-contrast=\"auto\">\u00a0qui pourraient b\u00e9n\u00e9ficier de\u00a0<\/span><b><span data-contrast=\"auto\">Alignement scientifique pr\u00e9coce avec l&#039;Agence europ\u00e9enne des m\u00e9dicaments<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><b><span data-contrast=\"auto\"><a href=\"http:\/\/regask.com\/fr\/\">RegASK<\/a>\u00a0est une plateforme de pointe d&#039;intelligence r\u00e9glementaire et d&#039;orchestration des flux de travail bas\u00e9e sur l&#039;IA agentielle<\/span><\/b><span data-contrast=\"auto\">\u00a0qui permet aux organisations mondiales op\u00e9rant dans des secteurs fortement r\u00e9glement\u00e9s, notamment les produits de consommation et les sciences de la vie, de s&#039;orienter de mani\u00e8re proactive dans des environnements r\u00e9glementaires complexes. En combinant\u00a0<\/span><b><span data-contrast=\"auto\">IA agentique avanc\u00e9e avec des experts impliqu\u00e9s<\/span><\/b><span data-contrast=\"auto\">,\u00a0<a href=\"http:\/\/regask.com\/fr\/\">RegASK<\/a>\u00a0livre\u00a0<\/span><b><span data-contrast=\"auto\">des informations pr\u00e9dictives exploitables en temps opportun et une automatisation de bout en bout<\/span><\/b><span data-contrast=\"auto\">, aidant les \u00e9quipes \u00e0 suivre les initiatives r\u00e9glementaires telles que les programmes d&#039;engagement de l&#039;EMA, \u00e0 pr\u00e9parer efficacement la documentation et \u00e0 rationaliser la conformit\u00e9 dans plus de\u00a0<\/span><b><span data-contrast=\"auto\">160 pays<\/span><\/b><span data-contrast=\"auto\">. <a href=\"http:\/\/regask.com\/fr\/\"><strong>En savoir plus <\/strong><\/a>ou<a href=\"https:\/\/regask.com\/fr\/reserver-une-demo\/\"><strong> r\u00e9servez une d\u00e9mo maintenant.<\/strong><\/a><\/span><strong>\u00a0<\/strong><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-212464744 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n<div class=\"row\"  id=\"row-225499926\">\n\n\t<div id=\"col-203838164\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<div class=\"is-divider divider clearfix\" style=\"margin-top:2em;margin-bottom:2em;max-width:20%;height:1px;background-color:#a5acd9;\"><\/div>\n<h3>FAQ<\/h3>\n\t<div id=\"gap-876103093\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-876103093 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<h4><span class=\"TextRun MacChromeBold SCXW267956491 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW267956491 BCX0\" data-ccp-parastyle=\"heading 3\">Quelles sont les nouvelles recommandations du CDE concernant les essais cliniques des vaccins contre la grippe\u00a0?<\/span><\/span><span class=\"EOP SCXW267956491 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:281,&quot;335559739&quot;:281}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-1358272704\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1358272704 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><strong>R\u00e9unions sur le portefeuille et la technologie (PTM)<\/strong> sont des r\u00e9unions virtuelles structur\u00e9es organis\u00e9es par <strong>Agence europ\u00e9enne des m\u00e9dicaments<\/strong> permettre aux grandes entreprises pharmaceutiques de discuter <strong>d\u00e9fis li\u00e9s au d\u00e9veloppement de portefeuilles de produits et technologies \u00e9mergentes<\/strong> avec l&#039;organisme de r\u00e9glementation.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-203838164 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-928297281\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4><span class=\"TextRun MacChromeBold SCXW184197477 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW184197477 BCX0\" data-ccp-parastyle=\"heading 3\">Qui peut candidater aux r\u00e9unions EMA sur le portefeuille et la technologie\u00a0?<\/span><\/span><span class=\"EOP SCXW184197477 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:281,&quot;335559739&quot;:281}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-1284823434\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1284823434 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Le programme PTM est ouvert \u00e0 <strong>grandes entreprises pharmaceutiques poss\u00e9dant de vastes portefeuilles de produits m\u00e9dicinaux.<\/strong> Les entreprises \u00e9ligibles doivent soumettre un formulaire de demande \u00e0 l&#039;EMA pour examen.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-928297281 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1496600851\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4><span class=\"TextRun MacChromeBold SCXW3460145 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW3460145 BCX0\" data-ccp-parastyle=\"heading 3\">Quelle est la date limite pour d\u00e9poser une demande de PTM en 2026\u00a0?<\/span><\/span><span class=\"EOP SCXW3460145 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:281,&quot;335559739&quot;:281}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-158451763\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-158451763 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Le <strong>La date limite de d\u00e9p\u00f4t des candidatures est le 30 avril 2026.<\/strong> Le <strong>L\u2019EMA communiquera les r\u00e9sultats des demandes d\u2019ici la fin du mois de mai 2026.,<\/strong> et les r\u00e9unions approuv\u00e9es auront lieu dans le <strong>seconde moiti\u00e9 de 2026. <\/strong><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1496600851 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1813358966\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4><span class=\"TextRun MacChromeBold SCXW14904628 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW14904628 BCX0\" data-ccp-parastyle=\"heading 3\">Comment peut-on\u00a0<\/span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW14904628 BCX0\" data-ccp-parastyle=\"heading 3\">RegASK<\/span><span class=\"NormalTextRun SCXW14904628 BCX0\" data-ccp-parastyle=\"heading 3\">\u00a0Comment aider les organisations \u00e0 g\u00e9rer des mises \u00e0 jour comme celle-ci\u00a0?<\/span><\/span><span class=\"EOP SCXW14904628 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:281,&quot;335559739&quot;:281}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-98075165\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-98075165 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"TextRun MacChromeBold SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><a href=\"http:\/\/regask.com\/fr\/\"><strong><span class=\"NormalTextRun SpellingErrorV2Themed SCXW253285960 BCX0\">RegASK<\/span><\/strong><\/a><span class=\"NormalTextRun SCXW253285960 BCX0\">\u00a0<strong>plateforme de veille r\u00e9glementaire IA agentique<\/strong><\/span><\/span><span class=\"TextRun SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW253285960 BCX0\">aide les entreprises pharmaceutiques\u00a0<\/span><\/span><span class=\"NormalTextRun SCXW253285960 BCX0\">moniteur<\/span><strong><span class=\"TextRun MacChromeBold SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW253285960 BCX0\">Annonces r\u00e9glementaires mondiales, possibilit\u00e9s d&#039;engagement et programmes de consultation<\/span><\/span><\/strong><span class=\"TextRun SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW253285960 BCX0\">\u00a0en temps r\u00e9el. Cela permet aux \u00e9quipes de r\u00e9glementation de\u00a0<\/span><span class=\"NormalTextRun SCXW253285960 BCX0\">identifier<\/span><span class=\"NormalTextRun SCXW253285960 BCX0\">\u00a0des initiatives telles que\u00a0<\/span><\/span><strong><span class=\"TextRun MacChromeBold SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW253285960 BCX0\">R\u00e9unions sur le portefeuille et la technologie de l&#039;EMA<\/span><\/span><\/strong><span class=\"TextRun SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW253285960 BCX0\"><strong>,<\/strong> coordonner la pr\u00e9paration interne et\u00a0<\/span><span class=\"NormalTextRun SCXW253285960 BCX0\">maintenir<\/span><span class=\"NormalTextRun SCXW253285960 BCX0\">\u00a0Pr\u00e9paration \u00e0 la conformit\u00e9 dans le cadre de pipelines mondiaux complexes.<\/span><\/span><span class=\"EOP SCXW253285960 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1813358966 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Le 10 mars 2026, l\u2019Agence europ\u00e9enne des m\u00e9dicaments (EMA) a annonc\u00e9 l\u2019ouverture des candidatures aux r\u00e9unions sur les portefeuilles et les technologies (PTM) pr\u00e9vues pour le second semestre 2026. Ce programme invite les grandes entreprises pharmaceutiques disposant d\u2019un large portefeuille de m\u00e9dicaments \u00e0 participer \u00e0 des discussions structur\u00e9es avec l\u2019agence. Ces r\u00e9unions virtuelles et gratuites visent \u00e0 aborder les d\u00e9fis li\u00e9s au d\u00e9veloppement des portefeuilles de produits, \u00e0 identifier les technologies \u00e9mergentes et de rupture, et \u00e0 contribuer \u00e0\u2026<\/p>","protected":false},"author":41,"featured_media":9666,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[33,538,35],"tags":[],"class_list":["post-9665","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-european-union","category-pharma-biotech-latest-insights"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.3 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>EMA Opens Applications for 2026 Portfolio Meetings<\/title>\n<meta name=\"description\" content=\"The EMA opens applications for 2026 Portfolio and Technology Meetings for large pharmaceutical companies. Apply by April 30.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/fr\/ema-ouvre-les-candidatures-pour-les-reunions-de-portefeuille-et-de-technologie-de-2026-destinees-aux-grandes-entreprises-pharmaceutiques\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EMA Opens Applications for 2026 Portfolio and Technology Meetings for Large Pharmaceutical Companies\" \/>\n<meta property=\"og:description\" content=\"The EMA opens applications for 2026 Portfolio and Technology Meetings for large pharmaceutical companies. Apply by April 30.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/fr\/ema-ouvre-les-candidatures-pour-les-reunions-de-portefeuille-et-de-technologie-de-2026-destinees-aux-grandes-entreprises-pharmaceutiques\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T03:12:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Shaffa Renaningtyas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Shaffa Renaningtyas\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/\"},\"author\":{\"name\":\"Shaffa Renaningtyas\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/b0e1938ef6f244f9f052a21f21cba1b6\"},\"headline\":\"EMA Opens Applications for 2026 Portfolio and Technolog&hellip;\",\"datePublished\":\"2026-03-18T03:12:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/\"},\"wordCount\":1002,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png\",\"articleSection\":[\"Regulatory News\",\"European Union\",\"Pharma and Biotech\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/\",\"name\":\"EMA Opens Applications for 2026 Portfolio Meetings\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png\",\"datePublished\":\"2026-03-18T03:12:29+00:00\",\"description\":\"The EMA opens applications for 2026 Portfolio and Technology Meetings for large pharmaceutical companies. Apply by April 30.\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png\",\"width\":800,\"height\":600,\"caption\":\"Ema Opens Applications 2026 Portfolio Technology Meetings Large Pharmaceutical Companies\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"Empowering Smarter Regulatory Decisions\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\",\"name\":\"RegASK\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"width\":401,\"height\":401,\"caption\":\"RegASK\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RegASKRegulatoryAffairs\\\/\",\"https:\\\/\\\/x.com\\\/ASKRegASK\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/RegASK\\\/\",\"https:\\\/\\\/www.youtube.com\\\/playlist?list=PL6yPC6gFqelkHbOeyUVKjtHOZXZ2LQbJd\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/b0e1938ef6f244f9f052a21f21cba1b6\",\"name\":\"Shaffa Renaningtyas\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"L&#039;EMA ouvre les candidatures pour les r\u00e9unions de portefeuille de 2026","description":"L\u2019EMA ouvre les candidatures pour les r\u00e9unions de portefeuille et de technologie 2026 destin\u00e9es aux grandes entreprises pharmaceutiques. Date limite de candidature\u00a0: 30 avril.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/fr\/ema-ouvre-les-candidatures-pour-les-reunions-de-portefeuille-et-de-technologie-de-2026-destinees-aux-grandes-entreprises-pharmaceutiques\/","og_locale":"fr_FR","og_type":"article","og_title":"EMA Opens Applications for 2026 Portfolio and Technology Meetings for Large Pharmaceutical Companies","og_description":"The EMA opens applications for 2026 Portfolio and Technology Meetings for large pharmaceutical companies. Apply by April 30.","og_url":"https:\/\/regask.com\/fr\/ema-ouvre-les-candidatures-pour-les-reunions-de-portefeuille-et-de-technologie-de-2026-destinees-aux-grandes-entreprises-pharmaceutiques\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2026-03-18T03:12:29+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png","type":"image\/png"}],"author":"Shaffa Renaningtyas","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Shaffa Renaningtyas","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/#article","isPartOf":{"@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/"},"author":{"name":"Shaffa Renaningtyas","@id":"https:\/\/regask.com\/#\/schema\/person\/b0e1938ef6f244f9f052a21f21cba1b6"},"headline":"EMA Opens Applications for 2026 Portfolio and Technolog&hellip;","datePublished":"2026-03-18T03:12:29+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/"},"wordCount":1002,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png","articleSection":["Regulatory News","European Union","Pharma and Biotech"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/","url":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/","name":"L&#039;EMA ouvre les candidatures pour les r\u00e9unions de portefeuille de 2026","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png","datePublished":"2026-03-18T03:12:29+00:00","description":"L\u2019EMA ouvre les candidatures pour les r\u00e9unions de portefeuille et de technologie 2026 destin\u00e9es aux grandes entreprises pharmaceutiques. Date limite de candidature\u00a0: 30 avril.","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png","width":800,"height":600,"caption":"Ema Opens Applications 2026 Portfolio Technology Meetings Large Pharmaceutical Companies"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Favoriser des d\u00e9cisions r\u00e9glementaires plus intelligentes","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/regask.com\/#organization","name":"RegASK","url":"https:\/\/regask.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","width":401,"height":401,"caption":"RegASK"},"image":{"@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","https:\/\/x.com\/ASKRegASK","https:\/\/www.linkedin.com\/company\/RegASK\/","https:\/\/www.youtube.com\/playlist?list=PL6yPC6gFqelkHbOeyUVKjtHOZXZ2LQbJd"]},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/b0e1938ef6f244f9f052a21f21cba1b6","name":"Shaffa Renaningtyas"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/9665","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/users\/41"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/comments?post=9665"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/9665\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media\/9666"}],"wp:attachment":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media?parent=9665"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/categories?post=9665"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/tags?post=9665"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}